These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36389667)

  • 21. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
    Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R
    Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
    He Y; Bouwstra R; Wiersma VR; de Jong M; Jan Lourens H; Fehrmann R; de Bruyn M; Ammatuna E; Huls G; van Meerten T; Bremer E
    Nat Commun; 2019 Feb; 10(1):533. PubMed ID: 30710089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
    Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
    Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
    VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
    Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
    Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.
    Yang H; Yan M; Li W; Xu L
    J Transl Med; 2022 Mar; 20(1):140. PubMed ID: 35317832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proinflammatory polarization strongly reduces human macrophage in vitro phagocytosis of tumor cells in response to CD47 blockade.
    Antonsen KW; Jensen AG; Carstensen M; Nejsum LN; Sorensen BS; Etzerodt A; Moestrup SK; Møller HJ
    Eur J Immunol; 2024 Jul; 54(7):e2350824. PubMed ID: 38593339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.
    Zhu D; Hadjivassiliou H; Jennings C; Mikolon D; Ammirante M; Acharya S; Lloyd J; Abbasian M; Narla RK; Piccotti JR; Stamp K; Cho H; Hariharan K
    MAbs; 2024; 16(1):2310248. PubMed ID: 38349008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD47 limits antibody dependent phagocytosis against non-malignant B cells.
    Gallagher S; Turman S; Lekstrom K; Wilson S; Herbst R; Wang Y
    Mol Immunol; 2017 May; 85():57-65. PubMed ID: 28208074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
    Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
    Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis.
    Wang J; Chai Q; Lei Z; Wang Y; He J; Ge P; Lu Z; Qiang L; Zhao D; Yu S; Qiu C; Zhong Y; Li BX; Zhang L; Pang Y; Gao GF; Liu CH
    EMBO Mol Med; 2024 Aug; 16(8):1755-1790. PubMed ID: 39030302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
    Barkal AA; Weiskopf K; Kao KS; Gordon SR; Rosental B; Yiu YY; George BM; Markovic M; Ring NG; Tsai JM; McKenna KM; Ho PY; Cheng RZ; Chen JY; Barkal LJ; Ring AM; Weissman IL; Maute RL
    Nat Immunol; 2018 Jan; 19(1):76-84. PubMed ID: 29180808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy.
    Zhao J; Zhong S; Niu X; Jiang J; Zhang R; Li Q
    Scand J Immunol; 2019 Nov; 90(5):e12804. PubMed ID: 31267559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
    Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
    Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macrophages are critical effectors of antibody therapies for cancer.
    Weiskopf K; Weissman IL
    MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
    Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
    Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.
    van Rees DJ; Brinkhaus M; Klein B; Verkuijlen P; Tool ATJ; Schornagel K; Treffers LW; van Houdt M; Kater AP; Vidarsson G; Gennery AR; Kuijpers TW; van Bruggen R; Matlung HL; van den Berg TK
    Blood Adv; 2022 Apr; 6(7):2156-2166. PubMed ID: 34942000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.